Search research articles
Contact Us
Filters
Showing results (91-100 of 148) with videos related to
Page
of 15
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
November 13, 2007
A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy
Helen A McNair, Vibeke N Hansen, Christopher C Parker, et al.
BJU International
|
November 8, 2008
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial
Nicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 7, 2004
Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer
Matthew R Sydes, Richard J Stephens, A Rollo Moore, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 1, 2022
In Regard to Shortall et al
Martin A Ebert, Marco Marcello, Angel Kennedy, et al.
BJU International
|
April 13, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial
Christopher C Parker, Matthew R Sydes, Malcolm D Mason, et al.
European Urology
|
April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial
David P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 23, 2009
Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397
Sarah L Gulliford, Kerwyn Foo, Rachel C Morgan, et al.
British Journal of Cancer
|
April 13, 2016
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity
Mahbubl Ahmed, Leila Dorling, Sarah Kerns, et al.
Frontiers in Oncology
|
August 15, 2020
Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials
Marco Marcello, James W Denham, Angel Kennedy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 3, 2020
Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials
Marco Marcello, James W Denham, Angel Kennedy, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 148) with videos related to
Sort By:
Page
of 15
International Journal of Radiation Oncology, Biology, Physics
|
November 13, 2007
A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy
Helen A McNair, Vibeke N Hansen, Christopher C Parker, et al.
BJU International
|
November 8, 2008
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial
Nicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 7, 2004
Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer
Matthew R Sydes, Richard J Stephens, A Rollo Moore, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 1, 2022
In Regard to Shortall et al
Martin A Ebert, Marco Marcello, Angel Kennedy, et al.
BJU International
|
April 13, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial
Christopher C Parker, Matthew R Sydes, Malcolm D Mason, et al.
European Urology
|
April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial
David P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 23, 2009
Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397
Sarah L Gulliford, Kerwyn Foo, Rachel C Morgan, et al.
British Journal of Cancer
|
April 13, 2016
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity
Mahbubl Ahmed, Leila Dorling, Sarah Kerns, et al.
Frontiers in Oncology
|
August 15, 2020
Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials
Marco Marcello, James W Denham, Angel Kennedy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 3, 2020
Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials
Marco Marcello, James W Denham, Angel Kennedy, et al.
Page
of 15